ArticleBMC primary care2025
The use of triptans and other acute treatments for the management of migraine in routine clinical practice in England: a retrospective cohort study using the Clinical Practice Research Datalink (CPRD).
Article in BMC primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine is a common and disabling neurological condition affecting around 10 million people in the UK. Optimal management has been indicated as a priority for improving migraine care in the UK, supported by clinical guidelines to provide clinicians with pathways for using acute and preventative treatments. There is a paucity of evidence on the real-world management of migraine, particularly with acute treatments.
methodsA retrospective cohort study using linked primary and secondary healthcare data in England (Clinical Practice Research Datalink [CPRD] Aurum and Hospital Episode Statistics [HES]). Adults with their first diagnosis of migraine between 1st January 2017 and 31st March 2019 were identified. Acute treatment patterns (prescribing rates, sequencing) and triptan use were described during a variable 12-month minimum follow-up period, up to 31st March 2020.
resultsA total of 62,205 patients met all eligibility criteria, of which 76.2% (n = 47,420) were female and the mean (SD) age at index was 39.8 (15.5) years. Almost 60% (n = 36,849; 59.2%) of the cohort received no prescription for acute treatment during follow-up, 23.1% (n = 14, 379) received acute treatment only and 17.6% (n = 10,977) received acute and preventative treatments. Triptans (25.7%; n = 15,971) and non-steroidal anti-inflammatory drugs (15.1%; n = 9,368) were the most frequently prescribed acute treatments during follow-up. Opioids were prescribed to 28.5% (n = 3,130) of the acute and preventative subgroup, and 15.8% (n = 2,267) of the acute only subgroup during follow-up. Only 1.8% (n = 1,127) were prescribed two different triptans with the median (IQR) time to second triptan of 7.8 (2.2–15.8) months. Of these, 17.2% (n = 198/1,149) subsequently cycled back to a previously prescribed triptan.
conclusionA large proportion of patients with migraine received no prescribed acute treatments, potentially indicating over-the-counter management or treatment with preventatives administered in secondary care. The most prescribed acute treatments were triptans. Very few were tried on more than one triptan, with some returning to earlier triptans. A significant proportion of our cohort were prescribed an opioid regimen, counter to UK clinical guidance. These observations suggest some variability to local guidance and international best practices in the treatment in migraine, highlighting a need for further guidance on the use of acute treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.